Patient-derived organoids to pick ADC payloads
Grow the patient's tumour in a dish and test which ADC payload kills it before choosing among three TROP2 ADCs.
Payload sensitivity (SN-38 vs DXd vs MMAE) varies by tumour and is not predicted by antigen level. Organoids retain drug sensitivity profiles and can be tested with free payloads within 2-3 weeks.
Pages like this
not linked directly; found by shared links- CompanyXilis
Shares Run the mouse or organoid trial at the same time as the human trial, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids.
- IdeaA public atlas of drug-pair responses across a thousand patient-derived organoids
Shares An open engine that ranks every drug pair by predicted synergy before anyone runs a trial, Functional (ex vivo) drug testing, Patient-derived organoids, Too many combinations to test.
- TechnologyPDAC organoid pharmacotyping
Shares Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- CompanySEngine Precision Medicine
Shares Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaSequential multiple-assignment randomised trials to find the best order of ADCs
Shares Sacituzumab govitecan, Datopotamab deruxtecan, Too many combinations to test, Antibody-drug conjugate (ADC).
- IdeaTumour-on-a-chip with blood flow to test whether big drugs actually get in
Shares Sacituzumab govitecan, Patient-derived organoids, Preclinical models that do not predict people, Antibody-drug conjugate (ADC).
- IdeaNeoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC
Shares Sacituzumab govitecan, Datopotamab deruxtecan, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares Sacituzumab govitecan, Datopotamab deruxtecan, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.